NIVF

MKT CAP:$1M

NewGenIvf Group Limited

Market Cap

$1M

Healthcare·Medical - Healthcare Plans· Thailand·NASDAQ

Healthcare·Medical·NASDAQ

Stock Price

$1.99-$6.05 (-75.25%)

Apr 23, 2026

Company Details

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising tradit...

CEO

Wing Fung Siu

IPO Date

Mar 18, 2022

Website

newgenivf.com

Key Metrics TTM

Revenue

$5M

+258.9% YoY

Net Income

$9M

EPS (Diluted)

$9.66

Free Cash Flow

-$7M

Revenue / Share

$9.27

Gross Margin

30.2%

Operating Margin

-153.3%

Net Margin

165.5%

FCF Margin

-123.5%

P/S

0.2x

P/E

0.1x

Earnings Reports

Q4 2025

Mar 31, 2026

$1M+11.8%EPS -$13.04

Q3 2025

Oct 9, 2025

$1M-12.9%EPS $28.60

Q4 2024

Apr 22, 2025

$1M-16.2%EPS -$4.60

Q3 2024

Sep 29, 2024

$1MEPS -$1.31

FY 2023

Aug 19, 2024

$5MEPS $12.44

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 21	$0	$0	-$2.0K
Q3 21	$0	$0	-$80
Q1 22	$0	$0	-$160.0K
Q2 22	$0	$0	-$122.7K
Q3 22	$0	$0	-$106.6K
Q4 22	$0	$0	-$115.6K
Q1 23	$0	$0	-$510.5K
Q2 23	$0	$0	-$367.0K
Q3 23	$0	$0	-$377.7K
Q4 23	$2M	$196.8K	-$1M
Q3 24	$1M	$646.2K	$216.3K
Q4 24	$1M	$359.4K	-$1M
Q3 25	$1M	$118.0K	-$3M
Q4 25	$1M	$524.0K	-$5M

Valuation

Quarter	P/S	P/E
Q2 21	—	—
Q3 21	—	—
Q1 22	—	—
Q2 22	—	—
Q3 22	—	1181602.9x
Q4 22	—	64036.7x
Q1 23	—	46775.1x
Q2 23	—	40617.9x
Q3 23	—	46065.8x
Q4 23	22570.1x	—
Q3 24	1601.7x	—
Q4 24	686.6x	—
Q3 25	2.3x	0.8x
Q4 25	0.9x	0.6x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 22	-$22.7K	-$22.7K
Q4 22	-$34.7K	-$34.7K
Q3 23	-$203.3K	-$203.3K
Q4 23	-$142.7K	-$142.7K
Q4 24	-$6M	-$6M

Capital Expenditures

Quarter	CapEx
Q3 22	$0
Q4 22	$0
Q3 23	$0
Q4 23	$4
Q4 24	$2.8K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	—	+5201.0%
Q4 22	—	+144447.5%
Q1 23	—	+219.0%
Q2 23	—	+199.1%
Q3 23	—	+254.5%
Q4 23	—	+2308.8%
Q3 24	—	+146.1%
Q4 24	—	+543.9%
Q3 25	—	+904.7%
Q4 25	-6.2%	+129.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 22	$0	—
Q4 22	$0	—
Q3 23	$0	—
Q4 23	$0	0.0%
Q4 24	$0	0.0%

OpEx Breakdown

Quarter	G&A	S&M	SG&A
Q2 21	—	—	$2.0K
Q3 21	—	—	$80
Q1 22	—	—	$160.0K
Q2 22	—	—	$122.7K
Q3 22	—	—	$106.6K
Q4 22	—	—	$115.6K
Q1 23	—	—	$510.5K
Q2 23	—	—	$367.0K
Q3 23	—	—	$377.7K
Q4 23	—	—	$1M
Q3 24	—	—	$429.9K
Q4 24	—	—	$1M
Q3 25	$2M	$187.2K	—
Q4 25	$5M	$694.3K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 21	$0	$0	$0
Q3 21	$0	$0	$0
Q4 22	$54.7K	$0	$54.7K
Q2 23	$121.6K	$38M	$39M
Q3 23	$38.8K	$39M	$39M
Q4 23	$54.1K	$0	$54.1K
Q3 24	$169.7K	$0	$169.7K
Q4 24	$457.7K	$0	$457.7K
Q3 25	$295.3K	$0	$295.3K
Q4 25	$758.6K	$0	$758.6K

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 21	262K	—	—
Q3 21	262K	0.0%	—
Q1 22	262K	0.0%	—
Q2 22	262K	0.0%	—
Q3 22	262K	0.0%	0.0%
Q4 22	262K	0.0%	0.0%
Q1 23	262K	0.0%	0.0%
Q2 23	262K	0.0%	0.0%
Q3 23	262K	0.0%	0.0%
Q4 23	262K	0.0%	0.0%
Q3 24	262K	0.0%	0.0%
Q4 24	588K	+124.4%	+124.4%
Q3 25	588K	0.0%	+124.4%
Q4 25	588K	0.0%	+124.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 21	—	—
Q3 21	—	—
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$21.7K	70
Q3 24	$21.0K	70
Q4 24	$16.8K	76
Q3 25	$16.9K	76
Q4 25	$16.4K	87

Revenue / Employee